Heather A. Jacene, Richard L. Wahl

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review


Hodgkin’s and non-Hodgkin’s lymphomas are lymphoid neoplasms arising from B cells, T cells, or NK (natural killer) cells. [18F]FDG PET/CT is more accurate for the primary staging of lymphoma particularly because it can detect disease in normal sized lymph nodes, the liver, spleen and bone marrow. A major advantage of [18F]FDG PET in determining the outcome of therapy is distinguishing active lymphoma from fibrosis/necrosis in residual masses. Posttherapy [18F]FDG PET provides important prognostic information and has been incorporated into the currently used criteria for evaluating response to therapy in lymphoma (revised International Workshop Criteria—IWC). Interim [18F]FDG PET/CT also provides prognostic information and is being evaluated for “risk-adapted therapy” in setting of clinical trials. Radioimmunotherapy with the anti-CD20 monoclonal antibodies, 90 Y-ibritumomab and 131 I-tositumomab, is effective therapy for non-Hodgkin’s lymphoma. Currently, radioimmunotherapy is used in the relapsed/refractory setting and also for consolidation after front-line chemotherapy in low-grade follicular lymphoma. Optimal usage of radioimmunotherapy and additional indications are areas of ongoing active investigations.

Original languageEnglish
Title of host publicationNuclear Oncology
Subtitle of host publicationPathophysiology and Clinical Applications
PublisherSpringer New York
Number of pages35
ISBN (Electronic)9780387488943
ISBN (Print)9780387488936
StatePublished - Jan 1 2013


  • Hodgkin’s lymphoma
  • Lymphomas and [<sup>18</sup>F]FDG PET/CT
  • Non-Hodgkin’s lymphoma
  • Radioimmunotherapy in lymphomas
  • [<sup>18</sup>F]FDG PET and lymphomas


Dive into the research topics of 'Lymphomas'. Together they form a unique fingerprint.

Cite this